Paul J. Bröckelmann

Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma

Paul J. Bröckelmann, Helen Goergen, Ulrich Keller et al. · JAMA Oncology · 2020 · 169 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +16

PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial

Peter Borchmann, Annette Plütschow, Carsten Kobe et al. · The Lancet Oncology · 2021 · 168 citations

Medicine, Oncology, Radiology +13

Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials

Stephanie Sasse, Paul J. Bröckelmann, Helen Goergen et al. · Journal of Clinical Oncology · 2017 · 142 citations

Medicine, Hematology, Oncology +12

Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials

Boris Böll, Helen Goergen, Karolin Behringer et al. · Blood · 2016 · 115 citations · Full text

Medicine, Geriatric Medicine, Oncology +13

Hematological immune related adverse events after treatment with immune checkpoint inhibitors

Rafaela Kramer, Anne Zaremba, Alvaro Moreira et al. · European Journal of Cancer · 2021 · 94 citations

Medicine, Hematology, Oncology +14